ALL Backbone in AYAs
Treatment of Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in Adolescents and Young Adults (AYAs)
Dana-Farber Cancer Institute
67 participants
Apr 3, 2026
INTERVENTIONAL
Conditions
Summary
The goal of this research study is to evaluate a chemotherapy regiment for the treatment of newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs). The names of the study drugs involved in this study are: * blinatumomab (a type of immunotherapy drug) * cyclophosphamide (a type of chemotherapy drug) * cytarabine (a type of antineoplastic agent) * dexamethasone (a type of synthetic glucocorticoid) * doxorubicin (a type of antineoplastic agent) * etoposide (a type of antineoplastic agent) * mercaptopurine (a type of antineoplastic agent) * methotrexate (a type of chemotherapy drug) * pegaspargase (a type of antineoplastic agent) * vincristine (a type of antineoplastic agent)
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A bispecific T-cell engager (BiTE) antibody, single-use vial via intravenous infusion, per standard of care
A modified enzyme L-asparaginase, single-use vial via intravenous infusion, per standard of care
An alkylating agent, single-use vial via intravenous infusion, per standard of care
An antineoplastic antimetabolite, multi-dose vial via intrathecal injection (through the spinal space), per standard of care
A synthetic glucocorticoid, tablets or single-use vials via orally or intravenous infusion (through the vein), per standard of care
An anthracycline antibiotic, single-use or multi-dose vials via intravenous infusion, per standard of care
A derivative of podophyllotoxin, multi-dose vial via intravenous infusion, per standard of care
A purine antagonist, tablet via orally, per standard of care
A folate analogue, multi-dose and single-use vials via intrathecal injection, per standard of care
A vinca alkaloid, single-use vials via intravenous injection, per standard of care
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07227584